Can a new pill keep HER2-Positive breast cancer from coming back?
NCT ID NCT03980054
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This phase III trial is testing whether the drug pyrotinib can further reduce the risk of breast cancer returning in women with HER2-positive early or locally advanced breast cancer who have already completed standard treatment with trastuzumab. Participants will be randomly assigned to receive either pyrotinib or a placebo once daily for one year. The study aims to see if pyrotinib improves the time without invasive cancer recurrence or death.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pyrotinib
- What this could lead to
- If successful, pyrotinib could offer a new way to reduce the chance of breast cancer returning in high-risk patients who have already received standard treatment.
- What could go wrong
- This is a large, late-stage trial, but results are not yet known. Pyrotinib may not prove more effective than placebo, and it could have side effects that outweigh its benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Cancer Hospital
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tape or a pressure vest ease Post-Radiation breast swelling?
- Personalized chemo: could tumor DNA hold the key to better breast cancer treatment?
- Can AI craft the perfect exercise plan for breast cancer survivors?
- Vitamin d gel on the scalp: a new hope against chemo hair loss?
- Can a lighter chemo combo spare older breast cancer patients?
- Can a radioactive tracer pinpoint Cancer's first stop?